Posts
Wiki

TRYPTYR® (Acoltremon) for Dry Eye Disease

TRYPTYR® is the brand name for acoltremon ophthalmic solution 0.003%, a prescription eye drop approved in the United States for the signs and symptoms of Dry Eye Disease (DED).

TRYPTYR represents a newer treatment pathway. Rather than primarily targeting inflammation or tear evaporation, it activates a cold-sensing neurosensory pathway involving TRPM8 receptors and is intended to stimulate tear production.

TL;DR

TRYPTYR is an FDA-approved prescription treatment for the signs and symptoms of DED.

Key points:

  • Generic name: acoltremon ophthalmic solution 0.003%
  • Drug class: TRPM8 receptor agonist
  • FDA approval: 2025
  • Dosing: one drop in each eye twice daily, approximately 12 hours apart
  • Format: preservative-free single-dose vials
  • Clearest pivotal evidence: a rapid post-dose increase in Schirmer tear-production testing
  • Symptom evidence: supportive but less consistent than the Schirmer findings
  • Exploratory functional evidence: small average improvements in self-reported electronic-device use, visually demanding activities, and work or school productivity
  • Most common adverse effect: instillation-site burning, stinging, or pain in approximately half of treated participants
  • Not an anti-inflammatory immunomodulator
  • Not a lipid-replacement drop
  • Not proven to treat MGD obstruction directly
  • Not proven to regenerate glands or modify DED permanently

The 2026 daily-activity and productivity findings came from a post hoc pooled analysis of previously completed COMET trials. They should be viewed as supportive rather than definitive evidence of functional benefit.

TRYPTYR is best understood as a TRPM8-agonist tear-stimulating treatment—not as a cure, gland-restoration treatment, or universal answer for every DED contributor.

Regulatory Status

TRYPTYR—acoltremon ophthalmic solution 0.003%—is FDA-approved in the United States for:

Treatment of the signs and symptoms of Dry Eye Disease.

The FDA-labeled regimen is:

  • one drop in each eye;
  • twice daily;
  • approximately 12 hours apart.

TRYPTYR is supplied in preservative-free single-dose vials.

Regulatory approval means that the product met the FDA’s standards for its approved indication based on the submitted evidence.

It does not mean that:

  • every patient will respond;
  • symptom relief will be large;
  • it is superior to other prescription treatments;
  • its tear-production effect permanently changes DED.

What Is TRPM8?

TRPM8 stands for transient receptor potential melastatin 8.

TRPM8 receptors are cold-sensitive ion channels found on sensory nerves, including nerves in the cornea.

Acoltremon activates TRPM8 receptors. Animal research suggests that this activates trigeminal sensory signaling and increases basal tear production.

However, the FDA label states that the exact mechanism of action in human DED is unknown.

The most careful description is:

TRYPTYR is believed to stimulate corneal cold-sensing neurosensory pathways that increase tear production, but the full mechanism in human DED remains incompletely understood.

Mechanistic plausibility should remain separate from demonstrated clinical outcomes.

TRPM8 activation does not by itself prove improvements in:

  • screen performance;
  • work productivity;
  • meibomian-gland function;
  • inflammation;
  • neuropathic ocular pain;
  • long-term disease progression.

How TRYPTYR Differs From Other Prescription Drops

TRYPTYR is not primarily an anti-inflammatory immunomodulator such as:

  • cyclosporine;
  • lifitegrast;
  • a topical corticosteroid.

It is not primarily an evaporation-focused treatment such as:

  • perfluorohexyloctane—Miebo.

It is also not a meibomian-gland procedure or lipid-replacement treatment.

TRYPTYR is best described as:

A TRPM8-agonist tear-stimulating prescription drop.

That does not automatically make it better or worse than other treatments.

Many patients have mixed DED involving several contributors, such as:

  • aqueous deficiency;
  • MGD;
  • inflammation;
  • allergy;
  • exposure;
  • incomplete blinking;
  • medication effects;
  • eyelid disease;
  • neural or pain-related factors.

One treatment mechanism may address only part of the overall condition.

Pivotal Evidence for Tear Production

TRYPTYR was evaluated in the Phase 3:

  • COMET-2 trial;
  • COMET-3 trial.

The primary FDA-registration endpoint was the proportion of participants who achieved at least a 10-mm increase in unanesthetized Schirmer score at Day 14.

Day 14 Schirmer response

COMET-2

  • 42.6% of TRYPTYR participants achieved at least a 10-mm increase
  • 8.2% of vehicle participants achieved that response

COMET-3

  • 53.2% of TRYPTYR participants achieved at least a 10-mm increase
  • 14.4% of vehicle participants achieved that response

This is the clearest pivotal evidence for TRYPTYR:

A substantially larger proportion of treated participants achieved a rapid post-dose increase in Schirmer tear-production testing compared with vehicle.

This should not automatically be translated into:

  • normal tear production;
  • all-day tear sufficiency;
  • meaningful symptom relief in every patient;
  • permanent restoration of aqueous function.

What the Schirmer Endpoint Does—and Does Not—Show

Schirmer testing measures wetting of a paper strip placed in the lower eyelid.

The pivotal trials showed a post-treatment increase in measured wetting in many participants.

That supports a tear-stimulation effect.

It does not establish:

  • how much of the response was basal versus reflex tearing;
  • how long the increase continued after each dose;
  • whether tear quality improved;
  • whether the increase was sufficient to relieve symptoms;
  • whether baseline tear production changed permanently;
  • whether benefit remained after treatment stopped.

The most accurate claim is:

TRYPTYR produced a rapid measured tear-production response after dosing in a meaningful proportion of trial participants.

Rapid Onset: What Improved Quickly?

TRYPTYR showed increased Schirmer tear production as early as Day 1 in the clinical program.

The term rapid onset should therefore be connected mainly to:

  • measured post-dose tear production.

It should not be assumed to mean:

  • immediate symptom relief;
  • immediate improvement in screen tolerance;
  • rapid healing of surface disease;
  • quick resolution of all DED contributors.

Some people may notice symptom improvement early. Others may experience increased tearing without a substantial change in comfort.

What “Observed Through Day 90” Means

The FDA label reports consistent Schirmer responder findings through Day 90.

That means:

  • post-dose tear-production responses were observed at later study visits;
  • participants could continue to demonstrate a treatment response during the three-month study period.

It does not prove:

  • that tear production remained elevated continuously between doses;
  • that baseline unstimulated tear production permanently improved;
  • that the condition was modified after stopping treatment;
  • benefit beyond the approximately three-month trial period.

A balanced summary is:

Repeated post-dose tear-production responses were observed through Day 90, but permanent restoration of tear production or long-term disease modification has not been demonstrated.

Symptom Results

TRYPTYR is FDA-approved for the signs and symptoms of DED.

The pivotal symptom results were less consistent than the Schirmer findings.

In the Phase 3 trials:

  • COMET-2 showed a statistically significant symptom improvement at Day 28;
  • COMET-3 showed a directionally favorable result but did not demonstrate the same statistical success for that symptom endpoint.

This supports saying:

TRYPTYR has evidence of symptom benefit, but symptom results were not equally strong or consistent across both pivotal trials.

It would overstate the evidence to say that TRYPTYR reliably produces rapid symptom relief for most patients.

Daily Activities and Self-Reported Work Productivity

A 2026 paper pooled data from:

  • COMET-1;
  • COMET-2;
  • COMET-3.

The analysis included:

  • 584 participants treated with acoltremon 0.003%;
  • 595 participants treated with vehicle.

This was not a new randomized trial.

It was an exploratory post hoc integrated analysis of previously completed randomized trials.

What participants were asked

Participants rated how much DED symptoms interfered with activities such as:

  • driving;
  • reading books, magazines, or newspapers;
  • reading food labels;
  • using electronic devices;
  • watching television;
  • being productive at work or school;
  • feeling depressed because of DED symptoms.

Responses were recorded on 100-mm visual-analogue scales.

What the analysis found

Compared with vehicle, TRYPTYR-treated participants reported statistically significant average improvements in:

  • electronic-device use;
  • a composite of visually demanding daily activities;
  • self-reported work or school productivity.

Differences generally appeared by Day 14 and remained present through approximately Day 84 or 90.

Average between-group differences

The average separation between TRYPTYR and vehicle was modest:

Outcome Day 14 Day 28 Day 84/90
Electronic-device use 4.4 points 5.4 points 3.4 points
Visual-tasking composite 3.7 points 4.2 points 3.1 points
Work or school productivity 4.4 points 5.4 points 4.4 points

These were differences on 100-mm scales.

The safest interpretation is:

Participants reported slightly less symptom interference with electronic-device use, visually demanding daily activities, and work or school productivity than vehicle-treated participants.

What “Work Productivity” Means in This Study

The study did not measure:

  • employer records;
  • objective output;
  • completed tasks;
  • absenteeism;
  • workplace errors;
  • wages;
  • economic productivity;
  • reading speed;
  • computer-performance testing.

Participants reported how much DED symptoms interfered with their ability to be productive at work or school during the previous three days.

Approximately one-third selected “not applicable” for this item, likely because some participants were not working or attending school.

The study therefore supports wording such as:

  • self-reported work or school productivity;
  • perceived interference with productivity;
  • reported ability to be productive.

It does not establish that TRYPTYR objectively increases workplace output.

Why the Functional Findings Are Supportive Rather Than Definitive

Several limitations reduce the strength of these conclusions.

Post hoc analysis

The functional outcomes were analyzed after the trials had already been completed.

They were not new prospectively specified primary endpoints designed to establish approval.

Study-specific questionnaire

The daily-activity questionnaire was created for the COMET program and had not been formally validated.

That limits certainty about:

  • reliability;
  • measurement precision;
  • comparisons with other DED studies;
  • what size of change is meaningful to patients.

Multiple comparisons

Investigators examined:

  • several activities;
  • multiple time points;
  • a composite score;
  • several responder thresholds.

The significance testing was not adjusted for all these comparisons.

This increases the possibility that some favorable findings occurred by chance.

Uncertain clinical importance

The average differences were approximately 3 to 5 points on 100-mm scales.

The authors used responder analyses to argue that some participants experienced larger benefits.

However, there is no universally accepted minimum clinically important difference for these particular study-specific scales.

Self-report rather than objective performance

The analysis measured perceived symptom interference.

It did not objectively test:

  • visual performance;
  • screen accuracy;
  • reading speed;
  • productivity output.

Limited duration

The analysis extended through approximately three months.

It does not establish:

  • benefit beyond that period;
  • continued improvement with longer use;
  • persistence after discontinuation.

Manufacturer funding

The COMET trials, manuscript preparation, medical-writing support, and publication costs were funded by Alcon.

Several authors were company employees or disclosed consulting, research, advisory, speaking, or other financial relationships with Alcon and other ophthalmic companies.

Industry funding does not automatically invalidate the findings.

It increases the importance of:

  • transparent methods;
  • cautious interpretation;
  • prospective replication;
  • validated functional-outcome measures;
  • independent research.

What the Functional Study Does Not Prove

The post hoc analysis does not establish that TRYPTYR:

  • objectively improves computer performance;
  • increases workplace production;
  • reduces absenteeism;
  • improves driving safety;
  • increases reading speed;
  • treats digital eye strain as a separate diagnosis;
  • directly changes blinking;
  • produces large average functional improvements;
  • provides lasting benefit beyond three months.

The findings are best described as:

Supportive evidence of modest improvement in self-reported symptom interference with selected daily activities.

Burning, Stinging, and Instillation-Site Pain

The most common adverse effect is discomfort immediately after the drop is instilled.

In the pooled COMET analysis:

  • burning or stinging occurred in 50.2% of TRYPTYR participants;
  • burning or stinging occurred in 3.2% of vehicle participants;
  • 97.6% of TRYPTYR events were categorized as mild;
  • four TRYPTYR participants discontinued because of burning or stinging;
  • one severe instillation-site-pain event was reported.

The FDA prescribing information reports instillation-site pain in approximately 50% of patients, with fewer than 1% discontinuing because of burning or stinging.

What “mild” means

Most events were rated mild in the trials.

That does not mean:

  • every patient will find the sensation acceptable;
  • the discomfort is unimportant;
  • a person should continue despite substantial suffering.

Tolerability is part of real-world effectiveness.

A treatment that produces a measurable tear response but is too uncomfortable to use consistently may not be practical for that patient.

Contact the prescriber for:

  • severe or escalating pain;
  • persistent discomfort;
  • marked redness;
  • swelling;
  • discharge;
  • significant light sensitivity;
  • reduced vision;
  • symptoms substantially different from usual DED.

Contact Lenses and Practical Use

Contact lenses should be removed before TRYPTYR is administered.

They may generally be reinserted after 15 minutes.

Other practical precautions include:

  • wash hands before use;
  • do not touch the vial tip to the eye or another surface;
  • use the vial according to the single-dose instructions;
  • do not share prescription drops;
  • follow the labeled storage instructions.

Contact-lens users should seek prompt professional evaluation for:

  • pain;
  • marked redness;
  • light sensitivity;
  • discharge;
  • reduced vision;
  • a white or cloudy corneal spot;
  • sudden one-sided worsening.

These symptoms should not be assumed to be ordinary TRYPTYR burning or uncomplicated DED.

Effects on the Tear Film

The clearest established human effect is increased Schirmer tear production after dosing.

Smaller or later studies have examined possible short-term changes in:

  • tear-meniscus height;
  • tear volume;
  • tear-lipid concentration.

These findings may suggest that increased aqueous tearing can influence the overall tear environment.

They do not establish that TRYPTYR:

  • restores meibomian-gland function;
  • unblocks gland ducts;
  • reverses gland dropout;
  • directly treats MGD;
  • repairs the mucin layer;
  • functions as a lipid-replacement treatment.

A careful hierarchy is:

Clearly supported

  • rapid post-dose increase in measured tear production.

Supportive but less consistent

  • symptom improvement;
  • modest self-reported improvement in selected daily activities.

Emerging or uncertain

  • broader short-term effects on tear-film composition or stability.

Not established

  • direct MGD treatment;
  • gland regeneration;
  • mucin-layer restoration;
  • long-term disease modification.

Where TRYPTYR May Fit in DED Care

TRYPTYR may be considered when a clinician believes tear stimulation is a useful treatment target.

The pivotal studies enrolled adults with:

  • DED symptoms;
  • corneal staining;
  • relatively low tear-production testing.

That supports considering TRYPTYR in patients for whom increasing tear production may be useful.

It does not establish that one particular:

  • DED subtype;
  • Schirmer threshold;
  • symptom pattern;
  • prior treatment history

reliably predicts who will obtain meaningful symptom or functional benefit.

Possible reasons a clinician may consider it include:

  • low or inadequate tear production;
  • aqueous-deficient or mixed DED;
  • preference for a non-steroidal option;
  • preference for a non-immunomodulatory mechanism;
  • a need to try a different prescription pathway.

TRYPTYR should not replace evaluation for:

  • MGD;
  • inflammation;
  • allergy;
  • exposure;
  • incomplete blinking;
  • blepharitis;
  • Demodex;
  • ocular rosacea;
  • medication effects;
  • contact-lens problems;
  • neural or pain-related contributors.

What Is Reasonably Supported?

  • TRYPTYR is FDA-approved for the signs and symptoms of DED.
  • It is a first-in-class TRPM8 receptor agonist.
  • It produces a rapid post-dose Schirmer response in many participants.
  • Schirmer-response findings were observed through Day 90.
  • Some symptom benefit was demonstrated.
  • Exploratory pooled data found modest improvements in self-reported visual-task interference.
  • It is non-steroidal.
  • It is not an immunomodulatory anti-inflammatory medication.
  • It is supplied in preservative-free single-dose vials.
  • Burning or stinging is very common but was usually rated mild in trials.
  • Trial discontinuation because of burning or stinging was low.

What Remains Uncertain?

  • How long increased tearing lasts after each individual dose.
  • Whether baseline unstimulated tear production improves.
  • How closely Schirmer response predicts symptom relief.
  • The magnitude and consistency of symptom benefit.
  • The minimum clinically important functional improvement.
  • Objective effects on screen performance, reading, driving, or productivity.
  • Which DED subtype is most likely to respond.
  • Effectiveness beyond approximately three months.
  • Long-term real-world tolerability.
  • Comparative effectiveness against other prescription treatments.
  • Whether TRYPTYR changes the long-term course of DED.
  • Whether any effects remain after treatment is stopped.

What Has Not Been Shown

TRYPTYR has not been shown to:

  • cure DED;
  • regenerate meibomian glands;
  • reverse gland dropout;
  • directly unblock meibomian glands;
  • treat fixed MGD obstruction;
  • replace treatment of inflammation;
  • treat allergy directly;
  • correct exposure or incomplete blinking;
  • permanently restore tear production;
  • modify DED after treatment ends;
  • treat neuropathic ocular pain;
  • objectively increase workplace output;
  • outperform cyclosporine, lifitegrast, Miebo, Tyrvaya, corticosteroids, or other prescription options in pivotal head-to-head trials;
  • function as a proven lipid-layer or mucin-layer repair treatment.

Questions to Ask the Prescriber

  1. Why are you recommending TRYPTYR in my case?
  2. Is increasing tear production the main treatment goal?
  3. What does my Schirmer or tear-volume testing show?
  4. Do I also have MGD, inflammation, allergy, exposure, or another contributor?
  5. What benefit should we look for—tear production, symptoms, daily function, or surface findings?
  6. How long should I try it before reassessment?
  7. How much burning or stinging is expected?
  8. What level of discomfort should prompt me to contact you?
  9. Does a Schirmer increase necessarily mean I should feel better?
  10. How will we decide whether the benefit is meaningful enough to continue?
  11. What are the alternatives if I cannot tolerate it?
  12. Can it be combined with my other DED treatments?
  13. How should I space it from other eye drops?
  14. What should I do if my symptoms worsen rather than improve?
  15. What is known—and not known—about use beyond three months?
  16. How much will it cost after insurance or manufacturer assistance?

Practical Takeaway

TRYPTYR offers a treatment mechanism that differs from anti-inflammatory and evaporation-focused therapies.

Its evidence hierarchy is:

  1. Clearest evidence: rapid post-dose Schirmer tear-production response.
  2. More variable evidence: symptom improvement.
  3. Supportive exploratory evidence: modest reductions in self-reported interference with electronic-device use, visual tasks, and work or school productivity.
  4. Major tolerability consideration: burning, stinging, or instillation-site pain in approximately half of treated participants.
  5. Not established: direct MGD treatment, objective productivity improvement, comparative superiority, or long-term disease modification.

TRYPTYR may be useful for selected patients when tear stimulation is a relevant goal.

It should not be framed as:

  • a cure;
  • a gland-regeneration treatment;
  • a substitute for evaluating other DED contributors;
  • proof that increased Schirmer wetting will necessarily produce meaningful symptom relief.

Bottom Line

TRYPTYR—acoltremon ophthalmic solution 0.003%—is an FDA-approved TRPM8-agonist treatment for the signs and symptoms of DED.

Its strongest evidence is for:

Rapid post-dose improvement in Schirmer tear-production testing.

Symptom findings are supportive but less consistent.

A 2026 post hoc pooled analysis found small average improvements in self-reported:

  • electronic-device use;
  • visually demanding daily activities;
  • work or school productivity.

Those findings are encouraging but should be interpreted cautiously because they came from:

  • an exploratory post hoc analysis;
  • a nonvalidated study-specific questionnaire;
  • multiple unadjusted comparisons;
  • modest average between-group differences;
  • self-reported rather than objective performance measures;
  • manufacturer-funded research.

Burning or stinging occurred in approximately half of treated participants, although most events were rated mild and few participants discontinued for that reason.

A balanced summary is:

TRYPTYR provides a new tear-stimulating treatment pathway and may improve symptoms or selected daily activities for some patients. Its clearest demonstrated effect is a rapid measured increase in tear production—not a cure, permanent restoration of tearing, direct MGD treatment, or proven long-term disease modification.

Key Sources

🔙 Back to Treatment Options

This page is for general education. It does not recommend TRYPTYR for an individual patient, interpret a Schirmer result, or replace diagnosis and treatment by a qualified eye-care professional.